However, a sub-analysis of the SELECT trial, a clinical study testing the efficacy of Selumetinib plus docetaxel in KRAS mutant NSCLC, has suggested a slight increase in progression-free and overall survival in patients with G12V and G12C KRAS mutant tumors compared to those harboring other KRAS oncogenic mutations [11,27]. Here, KRAS is linked to non-small cell lung carcinoma.